blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2884999

EP2884999 - METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  05.09.2025
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  02.10.2020
FormerGrant of patent is intended
Status updated on  11.05.2020
FormerExamination is in progress
Status updated on  25.03.2020
FormerGrant of patent is intended
Status updated on  17.11.2019
FormerExamination is in progress
Status updated on  04.01.2017
Most recent event   Tooltip05.09.2025Patent maintained (B2 publication)published on 08.10.2025  [2025/41]
Applicant(s)For all designated states
Fred Hutchinson Cancer Center
1100 Fairview Avenue North
Seattle, WA 98109 / US
For all designated states
Seattle Children's Hospital, dba Seattle Children's Research Institute
1900 9th Avenue
Seattle, WA 98101 / US
[2025/41]
Former [2022/33]For all designated states
Fred Hutchinson Cancer Center
1100 Fairview Avenue North
Seattle, WA 98109 / US
For all designated states
Seattle Children's Hospital, dba Seattle Children's Research Institute
1900 9th Avenue
Seattle, WA 98101 / US
Former [2020/45]For all designated states
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North, Mailstop J2-110
Seattle, WA 98109-1024 / US
For all designated states
Seattle Children's Hospital, dba Seattle Children's Research Institute
1900 9th Avenue
Seattle, WA 98101 / US
Former [2015/26]For all designated states
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North, Mailstop J2-110
Seattle, WA 98109-1024 / US
For all designated states
Seattle Children's Hospital, dba Seattle Children's Research Institute
1900 9th Avenue
Seattle, WA 98101 / US
Inventor(s)01 / RIDDELL, Stanley, R.
1763 268th Place SE
Sammamish, WA 98075 / US
02 / HUDECEK, Michael
Mozartstrasse 13/411
04107 Leipzig / DE
03 / JENSEN, Michael
3494 Pleasant Beach Drive
Bainbridge Island, WA 98110 / US
 [2015/26]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2025/41]
Former [2020/45]Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
Former [2015/26]MacLean, Martin Robert, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Application number, filing date13753495.420.08.2013
[2020/45]
WO2013US55862
Priority number, dateUS201261691117P20.08.2012         Original published format: US 201261691117 P
[2015/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014031687
Date:27.02.2014
Language:EN
[2014/09]
Type: A1 Application with search report 
No.:EP2884999
Date:24.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 27.02.2014 takes the place of the publication of the European patent application.
[2015/26]
Type: B1 Patent specification 
No.:EP2884999
Date:04.11.2020
Language:EN
[2020/45]
Type: B2 New European patent specification 
No.:EP2884999
Date:08.10.2025
Language:EN
[2025/41]
Search report(s)International search report - published on:EP27.02.2014
ClassificationIPC:C07K14/725, C07K16/28, C07K16/32, C07K14/715, C07K14/705
[2019/48]
CPC:
C07K14/705 (EP,IL,KR,RU,US); A61P1/00 (EP,IL); A61K38/1709 (RU);
C12N15/62 (KR,RU); A61K39/395 (RU); A61K40/11 (EP,IL,KR,RU,US);
A61K40/31 (EP,IL,KR,RU,US); A61K40/42 (KR); A61K40/4202 (EP,IL,RU,US);
A61K40/4205 (EP,IL,RU,US); A61K40/4211 (EP,IL,RU,US); A61P1/04 (EP,IL);
A61P1/18 (EP,IL); A61P11/00 (EP,IL); A61P13/08 (EP,IL);
A61P13/12 (EP,IL); A61P15/00 (EP,IL); A61P31/12 (EP,IL);
A61P35/00 (EP,IL); A61P35/02 (EP,IL); A61P37/02 (EP,IL);
C07K14/7051 (EP,IL,KR,US); C07K14/70521 (EP,IL,KR,US); C07K14/7151 (EP,IL,KR,US);
C07K16/2803 (EP,IL,KR,US); C07K16/32 (EP,IL,KR,US); C07K16/40 (IL,US);
C07K19/00 (RU); C12N15/63 (RU); C12N15/85 (KR);
C12N5/10 (RU); A61K2121/00 (KR); A61K2239/17 (EP,IL,RU,US);
A61K2239/31 (EP,IL,RU,US); A61K2239/48 (EP,IL,RU,US); A61K2300/00 (KR);
C07K2317/622 (EP,IL,KR,US); C07K2317/64 (EP,IL,KR,US); C07K2319/03 (EP,IL,US);
C07K2319/30 (EP,IL,US); C07K2319/70 (EP,IL,US) (-)
Former IPC [2015/26]A61K39/395, C07K14/705, C12N5/10, C12N15/62
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/26]
Extension statesBA20.03.2015
ME20.03.2015
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN FÜR EINE ZELL-IMMUNTHERAPIE[2015/26]
English:METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY[2015/26]
French:PROCÉDÉ ET COMPOSITIONS POUR L'IMMUNOTHÉRAPIE CELLULAIRE[2015/26]
Entry into regional phase20.03.2015National basic fee paid 
20.03.2015Designation fee(s) paid 
20.03.2015Examination fee paid 
Examination procedure20.03.2015Examination requested  [2015/26]
06.10.2015Amendment by applicant (claims and/or description)
13.06.2016Despatch of a communication from the examining division (Time limit: M06)
21.12.2016Reply to a communication from the examining division
21.06.2017Despatch of a communication from the examining division (Time limit: M06)
01.02.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
11.04.2018Reply to a communication from the examining division
27.11.2018Despatch of a communication from the examining division (Time limit: M06)
07.06.2019Reply to a communication from the examining division
18.11.2019Communication of intention to grant the patent
25.03.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.05.2020Communication of intention to grant the patent
22.09.2020Fee for grant paid
22.09.2020Fee for publishing/printing paid
22.09.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20201497.3  / EP3824905
EP25150326.4  / EP4537839
EP25216967.7
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.06.2016
Opposition(s)Opponent(s)01  09.04.2021  04.08.2021  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Klunker IP Patentanwälte PartG mbB, et al, et al
Destouchesstraße 68
80796 München / DE
 [2025/11]
Former [2022/30]
Opponent(s)01  09.04.2021  04.08.2021  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf, et al, et al
Mönchenwerter Straße 11
40545 Düsseldorf / DE
Former [2021/20]
Opponent(s)01  09.04.2021   
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
König, Gregor Sebastian, et al, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
16.08.2021Invitation to proprietor to file observations on the notice of opposition
25.02.2022Reply of patent proprietor to notice(s) of opposition
21.01.2025Legal effect of interlocutory decision in opposition
21.01.2025Date of oral proceedings
28.02.2025Despatch of interlocutory decision in opposition
28.02.2025Despatch of minutes of oral proceedings
03.06.2025Despatch of communication that the patent will be maintained as amended
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
11.04.2018Request for further processing filed
11.04.2018Full payment received (date of receipt of payment)
Request granted
24.04.2018Decision despatched
Fees paidRenewal fee
27.08.2015Renewal fee patent year 03
29.08.2016Renewal fee patent year 04
28.08.2017Renewal fee patent year 05
27.08.2018Renewal fee patent year 06
27.08.2019Renewal fee patent year 07
27.08.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  Tooltipdeleted
[2024/07]
Former [2021/45]AL04.11.2020
Cited inInternational search[XY] WO02077029  (HOPE CITY et al.)
 [XP] WO2012129514  (HUTCHINSON FRED CANCER RES et al.)
 [XY]   M. HUDECEK ET AL: "The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", BLOOD, vol. 116, no. 22, 25 November 2010 (2010-11-25), pages 4532 - 4541, XP055034816, ISSN: 0006-4971, DOI: 10.1182/blood-2010-05-283309

DOI:   http://dx.doi.org/10.1182/blood-2010-05-283309
 [XY]   TILL BRIAN G ET AL: "Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells", BLOOD, vol. 112, no. 6, September 2008 (2008-09-01), pages 2261 - 2271, XP002718371, ISSN: 0006-4971

DOI:   http://dx.doi.org/10.1182/blood-2007-12-128843
 [XY]   PHILIPP KOEHLER ET AL: "Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia", ADVANCES IN HEMATOLOGY, vol. 180, no. 9, 1 January 2012 (2012-01-01), pages 6365 - 13, XP055094721, ISSN: 1687-9104, DOI: 10.1073/pnas.0710198105

DOI:   http://dx.doi.org/10.1155/2012/595060
 [XY]   E. J. CHEADLE ET AL: "Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 4, 20 January 2010 (2010-01-20), pages 1885 - 1896, XP055034825, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901440

DOI:   http://dx.doi.org/10.4049/jimmunol.0901440
by applicantUS6040177
 US9108442
 US9405601
   ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, vol. 266, 1996, pages 460 - 480
   BEJCEK ET AL., CANCER RES, 2005
   PEZUTTO ET AL., JI, 1987
   LUPTON S. D. ET AL., MOL. AND CELL BIOL., vol. 11, 1991, pages 6
   RIDDELL ET AL., HUMAN GENE THERAPY, vol. 3, 1992, pages 319 - 338
   RIDDELL SR; GREENBERG PD: "The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells", J IMMUNOL METHODS, vol. 128, no. 2, 17 April 1990 (1990-04-17), pages 189 - 201, XP025462287, DOI: doi:10.1016/0022-1759(90)90210-M

DOI:   http://dx.doi.org/10.1016/0022-1759(90)90210-M
   HUDECEK M ET AL., BLOOD, 2010
   HUDECEK M ET AL., BLOOD, vol. 116, no. 22, 13 August 2010 (2010-08-13), pages 4532 - 41
   FITZER-ATTAS CJ ET AL.: "Hamessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variablc domain rcccptors: optimal design for T ccll activation", J IMMUNOL., vol. 160, no. 1, 29 April 1998 (1998-04-29), pages 145 - 54
   CHO, NATURE, vol. 421, 2003, pages 756
OppositionWO2014031687
 US201261691117
 WO2011056894
 WO2011056894
   HUDECEK ET AL.: "Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells", CLINICAL CANCER RESEARCH, vol. 19, no. 12, 2013, pages 3153 - 3164, XP055177780, DOI: 10.1158/1078-0432.CCR-13-0330 * D3a Supplemental Material by Hudecek et al., 2013 (D3) *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0330
   HUDECEK M, M-T LUPO-STANGHELLINI; KOSASIH P L; SOMMERMEYER D; JENSEN M C; RADER C; RIDDELL S R: "Supplementary data: Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 12, 15 June 2013 (2013-06-15), US, pages 1 - 8, XP093239914, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0330

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0330
   D6 - Assignments of Michael Hudecek dated August 03, 2013, of Michael Jensen dated August 09, 2013 and of Stanley R. Riddell dated July 29, 2013
   D7 - Expert declaration of Hon. Randall R. Rader (July 30, 2021), the former Chief Judge on the United States Court of Appeals for the Federal Circuit, accompanied by
   MICHAEL C. MILONE, JONATHAN D. FISH, CARMINE CARPENITO, RICHARD G. CARROLL, GWENDOLYN K. BINDER, DAVID TEACHEY, MINU SAMANTA, MEHD: "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", MOLECULAR THERAPY, vol. 17, no. 8, 1 August 2009 (2009-08-01), pages 1453 - 1464, XP002732433, ISSN: 1525-0016, DOI: 10.1038/MT.2009.83

DOI:   http://dx.doi.org/10.1038/MT.2009.83
   MARC CARTELLIERI, MICHAEL BACHMANN, ANJA FELDMANN, CLAUDIA BIPPES, SLAVA STAMOVA, REBEKKA WEHNER, ACHIM TEMME, MARC SCHMITZ: "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, HINDAWI PUB. CORP., vol. 2010, no. 956304, 1 January 2010 (2010-01-01), pages 1 - 13, XP002673541, ISSN: 1110-7243, DOI: 10.1155/2010/956304

DOI:   http://dx.doi.org/10.1155/2010/956304
   CAMERON J TURTLE, HUDECEK MICHAEL, JENSEN MICHAEL C, RIDDELL STANLEY R: "Engineered T cells for anti-cancer therapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD., GB, vol. 24, no. 5, 1 October 2012 (2012-10-01), GB , pages 633 - 639, XP055272888, ISSN: 0952-7915, DOI: 10.1016/j.coi.2012.06.004

DOI:   http://dx.doi.org/10.1016/j.coi.2012.06.004
   KOCHENDERFER J N; ROSENBERG S A: "Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors", NATURE REVIEWS CLINICAL ONCOLOGY, NATURE, NY, US, vol. 10, no. 5, 1 May 2013 (2013-05-01), NY, US , pages 267 - 276, XP009170183, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2013.46

DOI:   http://dx.doi.org/10.1038/nrclinonc.2013.46
   BRIDGEMAN JOHN S; HAWKINS ROBERT E; HOMBACH ANDREAS A; ABKEN HINRICH; GILHAM DAVID E: "Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy", CURRENT GENE THERAPY, BENTHAM SCIENCE PUBLISHERS LTD., NL, vol. 10, no. 2, 1 April 2010 (2010-04-01), NL , pages 77 - 90, XP009187229, ISSN: 1566-5232, DOI: 10.2174/156652310791111001

DOI:   http://dx.doi.org/10.2174/156652310791111001
   KEVIN J. CURRAN, HOLLIE CURRAN, RENIER PEGRAM, BRENTJENS: "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions", THE JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 14, no. 6, 27 June 2012 (2012-06-27), US , pages 405 - 415, XP055081970, ISSN: 1099-498X, DOI: 10.1002/jgm.2604

DOI:   http://dx.doi.org/10.1002/jgm.2604
   GIANPIETRO DOTTI, SAVOLDO BARBARA, BRENNER MALCOLM: "Review Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: ''Are We Nearly There Yet?''", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 20, no. 11, 1 November 2009 (2009-11-01), GB , pages 1229 - 1239, XP055122213, ISSN: 1043-0342, DOI: 10.1089/hum.2009.142

DOI:   http://dx.doi.org/10.1089/hum.2009.142
   SADELAIN M, RIVIERE I, BRENTJENS R: "TARGETING TUMOURS WITH GENETICALLY ENHANCED T LYMPHOCYTES", NATURE REVIEWS CANCER, NATURE PUB. GROUP, LONDON, vol. 03, no. 01, 1 January 2003 (2003-01-01), London , pages 35 - 45, XP009026020, ISSN: 1474-175X, DOI: 10.1038/nrc971

DOI:   http://dx.doi.org/10.1038/nrc971
   MICHAEL HUDECEK, ANDERSON JR LARRY D, NISHIDA TETSUYA, RIDDELL STANLEY R: "Adoptive T-cell therapy for B-cell malignancies", EXPERT REVIEW OF HEMATOLOGY, EXPERT REVIEWS LTD, UK, vol. 2, no. 5, 1 October 2009 (2009-10-01), UK , pages 517 - 532, XP055034818, ISSN: 1747-4086, DOI: 10.1586/ehm.09.47

DOI:   http://dx.doi.org/10.1586/ehm.09.47
   "Antigen binding molecules: antibodies and t-cell receptors", 1 January 1996, ACADEMIC PRESS, ISBN: 0-12-034249-9, article JIRI NOVOTNY, JRGEN BAJORATH : "Computational Biochemistry of Antibodies and T-Cell Receptors", pages: 222 - 225, XP055920396 * , excerpt (pp. 222-225) *
   MARE WHITLOW, BRIAN A. BELL, SHEAU-LINE FENG, DAVID FILPULA, KARL D. HARDMAN, STEVEN L. HUBERT, MICHELE L. ROLLENCE, JAMES F. WOOD: "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD UNIVERSITY PRESS, vol. 6, no. 8, 1 January 1993 (1993-01-01), pages 989 - 995, XP055671247, ISSN: 1741-0126, DOI: 10.1093/protein/6.8.989

DOI:   http://dx.doi.org/10.1093/protein/6.8.989
   MARCO L. DAVILA, RENIER BRENTJENS, XIUYAN WANG, ISABELLE RIVIèRE, MICHEL SADELAIN: "How do CARs work? : Early insights from recent clinical studies targeting CD19", ONCOIMMUNOLGY, LANDES BIOSCIENCE, US, vol. 1, no. 9, 1 December 2012 (2012-12-01), US , pages 1577 - 1583, XP055445746, ISSN: 2162-4011, DOI: 10.4161/onci.22524

DOI:   http://dx.doi.org/10.4161/onci.22524
   CARLOS A RAMOS, GIANPIETRO DOTTI: "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 11, no. 7, 1 July 2011 (2011-07-01), pages 855 - 873, XP055122639, ISSN: 14712598, DOI: 10.1517/14712598.2011.573476

DOI:   http://dx.doi.org/10.1517/14712598.2011.573476
   "Epitope Mapping Protocols : Second Edition", vol. 1, 20 May 2009, HUMANA PRESS, ISBN: 978-1-934115-17-6, ISSN: 1064-3745, article REINEKE ULRICH, MIKE SCHUTKOWSKI: "Front Matter: Epitope mapping protocols", pages: i - xiii, XP093239938, DOI: 10.1385/0896033759
   ROB C. AALBERSE, JANINE SCHUURMAN: "IgG4 breaking the rules", CANCER RESEARCH, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 105, no. 1, 1 January 2002 (2002-01-01), GB , pages 9 - 19, XP055115132, ISSN: 0019-2805, DOI: 10.1046/j.0019-2805.2001.01341.x

DOI:   http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x
   C. M. KOWOLIK, M. S. TOPP, S. GONZALEZ, T. PFEIFFER, S. OLIVARES, N. GONZALEZ, D. D. SMITH, S. J. FORMAN, M. C. JENSEN, L. J.N. CO: "CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells", CANCER RESEARCH, UNIVERSITY OF CHICAGO PRESS, vol. 66, no. 22, 15 November 2006 (2006-11-15), pages 10995 - 11004, XP055044266, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-0160

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-06-0160
   L. J. N. COOPER: "T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 101, no. 4, 15 February 2003 (2003-02-15), US , pages 1637 - 1644, XP055204920, ISSN: 0006-4971, DOI: 10.1182/blood-2002-07-1989

DOI:   http://dx.doi.org/10.1182/blood-2002-07-1989
   IMAI C; MIHARA K; ANDREANSKY M; NICHOLSON I C; PUI C-H; GEIGER T L; CAMPANA D: "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 18, no. 4, 1 April 2004 (2004-04-01), London, pages 676 - 684, XP002579934, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2403302

DOI:   http://dx.doi.org/10.1038/sj.leu.2403302
   KLESMITH JUSTIN R., WU LAN, LOBB ROY R., RENNERT PAUL D., HACKEL BENJAMIN J.: "Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 58, no. 48, 3 December 2019 (2019-12-03), pages 4869 - 4881, XP055920399, ISSN: 0006-2960, DOI: 10.1021/acs.biochem.9b00808

DOI:   http://dx.doi.org/10.1021/acs.biochem.9b00808
   GU RUNXIA, LIU FANG, ZOU DEHUI, XU YINGXI, LU YANG, LIU BINGCHENG, LIU WEI, CHEN XIAOJUAN, LIU KAIQI, GUO YE, GONG XIAOYUAN, LV RU: "Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 13, no. 1, 1 December 2020 (2020-12-01), London UK , pages 122 - 13, XP055920402, ISSN: 1756-8722, DOI: 10.1186/s13045-020-00953-8

DOI:   http://dx.doi.org/10.1186/s13045-020-00953-8
   NICHOLSON I C ET AL: "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 34, no. 16-17, 1 November 1997 (1997-11-01), GB , pages 1157 - 1165, XP002220979, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(97)00144-2

DOI:   http://dx.doi.org/10.1016/S0161-5890(97)00144-2
   KALOS M; LEVINE B L; PORTER D L; KATZ S; GRUPP S A; BAGG A; JUNE C H: "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 3, no. 95, 10 August 2011 (2011-08-10), pages 95ra73.1 - 95ra73.11, XP002667262, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.3002842

DOI:   http://dx.doi.org/10.1126/scitranslmed.3002842
   DAVID L. PORTER, BRUCE L. LEVINE, MICHAEL KALOS, ADAM BAGG, CARL H. JUNE: "Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 365, no. 8, 25 August 2011 (2011-08-25), US , pages 725 - 733, XP055579937, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1103849

DOI:   http://dx.doi.org/10.1056/NEJMoa1103849
   CARL H. JUNE, BRUCE R. BLAZAR, JAMES L. RILEY: "Engineering lymphocyte subsets: tools, trials and tribulations", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 9, no. 10, 1 October 2009 (2009-10-01), London, pages 704 - 716, XP055145648, ISSN: 1474-1733, DOI: 10.1038/nri2635

DOI:   http://dx.doi.org/10.1038/nri2635
   MARIE BLEAKLEY, STANLEY R RIDDELL: "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, vol. 89, no. 3, 1 March 2011 (2011-03-01), AU , pages 396 - 407, XP055663061, ISSN: 0818-9641, DOI: 10.1038/icb.2010.124

DOI:   http://dx.doi.org/10.1038/icb.2010.124
   CAMERON J TURTLE; STANLEY R RIDDELL;: "Genetically retargeting CD8lymphocyte subsets for cancer immunotherapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD., GB, vol. 23, no. 2, GB , pages 299 - 305, XP028160383, ISSN: 0952-7915, DOI: 10.1016/j.coi.2010.12.012

DOI:   http://dx.doi.org/10.1016/j.coi.2010.12.012
   CLAUDIO ORTOLANI: "Flow Cytometry of Hematological Malignancies", 15 July 2011, WILEY, ISBN: 978-1-4443-9806-9, article ORTOLANI CLAUDIO: "CD19 Antigen", pages: 48 - 50, XP093240024, DOI: 10.1002/9781444398069.ch1
   ROBERTS M R; QIN L; ZHANG D; SMITH D H; TRAN A C; DULL T J; GROOPMAN J E; CAPON D J; BYRN R A; FINER M H: "TARGETING OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CELLS BY CD8+T LYMPHOCYTES ARMED WITH UNIVERSAL T-CELL RECEPTORS.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 84, no. 9, 1 November 1994 (1994-11-01), US , pages 2878 - 2889, XP000601097, ISSN: 0006-4971, DOI: 10.1182/blood.v84.9.2878.2878

DOI:   http://dx.doi.org/10.1182/blood.v84.9.2878.2878
   MITSUYASU R T; ANTON P A; DEEKS S G; SCADDEN D T; CONNICK E; DOWNS M T; BAKKER A; ROBERTS M R; JUNE C H; JALALI S; LIN A A; PENNAT: "Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 96, no. 3, 1 August 2000 (2000-08-01), US , pages 785 - 793, XP002953226, ISSN: 0006-4971, DOI: 10.1182/blood.V96.3.785

DOI:   http://dx.doi.org/10.1182/blood.V96.3.785
   HUDECEK MICHAEL, MARIA-TERESA LUPOSTANGHELLINI, JIAHUI YANG, PAULA KOSASIH, PAULINA PASZKIEWICZ, JEANNETTE BET, DAVID G MALONEY, M: "5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, ELSEVIER, NL, vol. 11, no. S2, 1 October 2011 (2011-10-01), NL , pages S280 - S281, XP093240035, ISSN: 2152-2650, DOI: 10.1016/j.clml.2011.09.207
   D39 - Declaration of Christopher Rennie-Smith including CV
   D40 - Declaration of Dr Jeffrey C. Pepe, Esq. including Annexes A-C
   D41 - Letter to the International Bureau pursuant to Rule 91 PCT
   D42 - Declaration of Dr Stanley R. Riddell including CV
   ZOLA H; MACARDLE P J; BRADFORD T; WEEDON H; YASUI H; KUROSAWA Y: "Preparation and characterization of a chimeric CD19 monoclonal antibody", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, vol. 69, no. 6, 1 December 1991 (1991-12-01), AU , pages 411 - 422, XP008115309, ISSN: 0818-9641, DOI: 10.1038/icb.1991.58

DOI:   http://dx.doi.org/10.1038/icb.1991.58
   D45 - Legal opinion of Derk Visser 14 May 2022
   D46 - Hudecek agreement
   D47 - Sequence analysis of D29
   D48a - Assignments of the priority application US 61/691,117 from Fred Hutchinson Cancer Research Center to Michael Hudecek and Stanley R. Riddell
   D48b - Assignments of the priority application US 61/691,117 from Seattle Childrens Hospital to Michael Jensen
   D49.1-28 Armitage Exhibit 1-28
   D50 - Stoll Declaration
   D50.1-34 Stoll Exhibit 1-34
   HUDECEK MICHAEL; SILVA ANNE; KOSASIH PAULA L.; CHEN YVONNE Y.; TURTLE CAMERON J.; JENSEN MICHAEL C.; RIDDELL STANLEY R.: "The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 120, no. 21, 16 November 2012 (2012-11-16), US , pages 951, XP086660651, ISSN: 0006-4971, DOI: 10.1182/blood.V120.21.951.951

DOI:   http://dx.doi.org/10.1182/blood.V120.21.951.951
   M. HUDECEK, D. SOMMERMEYER, P. L. KOSASIH, A. SILVA-BENEDICT, L. LIU, C. RADER, M. C. JENSEN, S. R. RIDDELL: "The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 3, no. 2, 1 February 2015 (2015-02-01), US , pages 125 - 135, XP055177300, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0127

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-14-0127
   DONALD B KOHN, GIANPIETRO DOTTI, RENIER BRENTJENS, BARBARA SAVOLDO, MICHAEL JENSEN, LAURENCE JN COOPER, CARL H JUNE, STEVEN ROSENB: "CARs on Track in the Clinic", MOLECULAR THERAPY, ELSEVIER, vol. 19, no. 3, 1 March 2011 (2011-03-01), pages 432 - 438, XP055122212, ISSN: 1525-0016, DOI: 10.1038/mt.2011.1

DOI:   http://dx.doi.org/10.1038/mt.2011.1
   HOMBACH A; HOMBACH A A; ABKEN H: "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 17, no. 10, 17 June 2010 (2010-06-17), GB , pages 1206 - 1213, XP037770859, ISSN: 0969-7128, DOI: 10.1038/gt.2010.91

DOI:   http://dx.doi.org/10.1038/gt.2010.91
   STROHL, W.R.: "Optimization of Fc-mediated effector functions of monoclonal antibodies", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 20, no. 6, 1 December 2009 (2009-12-01), GB , pages 685 - 691, XP026778879, ISSN: 0958-1669, DOI: 10.1016/j.copbio.2009.10.011

DOI:   http://dx.doi.org/10.1016/j.copbio.2009.10.011
   D56 - Decision by the Board of Appeal T2360-19 3.3.08
   D57 - Ramsey decalaration and exhibits
   MICHAEL C. MILONE, JONATHAN D. FISH, CARMINE CARPENITO, RICHARD G. CARROLL, GWENDOLYN K. BINDER, DAVID TEACHEY, MINU SAMANTA, MEHD: "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", MOLECULAR THERAPY, vol. 17, no. 8, 1 August 2009 (2009-08-01), pages 1453 - 1464, XP002732433, ISSN: 1525-0016, DOI: 10.1038/MT.2009.83

DOI:   http://dx.doi.org/10.1038/MT.2009.83
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.